OBI Pharma Australia Pty Ltd announces the clearance of Adogloxad Simolenin (OBI-822) for a Phase III clinical study in Australia
Date of occurrence of the event: Oct 29, 2018 Company name: OBI Pharma Australia Pty Ltd Relationship to the Company (please enter “head office” or “subsidiaries”): subsidiary Reciprocal shareholding ratios: …
OBI received notice from patent attorney’s office that product patent for OBI-822 named “Compound and Compositions of Carbohydrate Vaccine and Uses Thereof” has been approved by Taiwan Intellectual Property Office
Date of occurrence of the event: Oct 01, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study
Date of occurrence of the event: Sept 28, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Correction on previous announcement: “Clarification on the news article by Commercial Times” to “United Daily News”
Date of occurrence of the event: Sept 20, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Clarification on the news article by Commercial Times
Date of occurrence of the event: Sept 20, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Second Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid and liquid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan. September 18, 2018 /PRNewswire/ — OBI …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Date of occurrence of the event: Sept 19, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities
1.Date of the event: Sep 5, 2018 2.Time: 14:30:00 CST 3.Location：Masterlink Securities (Address: No.97-11, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106, Taiwan) 4.Summary: OBI Pharma Inc. to …
OBI received notice from patent attorney’s office that product patent for OBI-3424 named “DNA alkylating agents” has been approved by IP Australia
Date of occurrence of the event: Aug 15, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Clarification on the news article by Commercial Times
Date of occurrence of the event: Jul 28, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …